68Ga-DOTATATE Neuroblastoma Imaging Pilot

Summary

Neuroblastoma is the most frequent extracranial childhood tumor, with an annual incidence of approximately 10.2 per million children. Staging of the disease can be done by different imaging strategies (CT, MRI, scintigraphy and PET/CT). Discrepancies may be observed among these different strategies resulting in different treatment strategies. The goal of this study is to assess the feasibility and safety of 68Ga-DOTATATE and to compare it to 123I-MIBG when investigating neuroblastoma.

Eligibility

Inclusion Criteria:

* Newly suspected or biopsy-proven neuroblastoma or recurrence of neuroblastoma
* Planned 123I-MIBG imaging
* Able and willing to provide signed informed consent in French or English (for the adult candidates or the parent/legal tutor of the pediatric candidates)
* Aged between 1 day and 21 years old (inclusively).

Exclusion Criteria:

* History of another cancer in the past 5 years other than non-melanomatous skin cancer.
* Currently under a randomized control trial with unknown allocation;
* Currently under treatment;
* Medical/surgical intervention on the tumour between 123I-MIBG and 68Ga-DOTATATE PET/CT scan.
* Medically unstable or unable to undergo scan.
* Pregnancy (breastfeeding is not an exclusion criterion but needs to be stopped for at least 12 hours after 68Ga-DOTATATE injection).
* Prior allergic reaction to somatostatin analogues

Conditions2

Browse More Trials